Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amiodarone Velpharm
- Development stage
- Unknown
- Lead developer
- Velpharm
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Amiodarone Velpharm (Амиодарон Велфарм) is an approved generic formulation of amiodarone, a Class III antiarrhythmic agent developed and manufactured by the Russian pharmaceutical company Velpharm. Formulated as oral tablets and intravenous concentrates, the drug is indicated for the treatment and prevention of severe cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, and atrial flutter. Amiodarone acts as a multi-channel blocker; while primarily classified as a Class III agent due to its blockade of potassium channels (which prolongs cardiac action potential duration and refractoriness), it also exhibits Class I (sodium channel blockade), Class II (non-competitive beta-adrenergic receptor antagonism), and Class IV (calcium channel blockade) electrophysiological properties.
- Brand names
- Amiodarone VelpharmАмиодарон Велфарм
- Other names
- amiodaroneamiodarone hydrochloride
02
Targets
ADRA1 (Alpha-1 adrenergic receptor family)ADRB1 (β1)KCNH2 (Voltage-gated potassium channel subfamily H member 2)LTCC (Voltage-gated calcium channel (L-type))ADRA1A (α1A)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Amiodarone Velpharm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amiodarone Velpharm.